According to regulatory requirements, we simultaneously conducted an independent single-arm phase I study in China to determine the safety, tolerability, pharmacokinetics, and clinical activity of A166 in Chinese patients with HER2-expressing locally advanced or metastatic solid tumours. Overall, the stud...